1 ; WHAT PHYSICAL PATIENTS ARE EFFECTS FROM THE CALCIUM ON MUCUS CF PROPERTIES OF
2 ; AND CAN EFFECTS HYPERSECRETION SUBMUCOSAL GLANDS TRACT THE DISTINGUISH ON BETWEEN MUCUS INFECTION CF ONE RESPIRATORY IN OF
3 ; OF DIFFERENT SUBJECTS SALIVARY ARE FROM HOW GLYCOPROTEINS NORMAL CF PATIENTS THOSE
4 ; WHAT SECRETIONS IS THE COMPOSITION LIPID CF RESPIRATORY OF
5 ; ABNORMAL IS CF MUCUS
6 ; WHAT PHYSICAL PATIENTS AGENTS VISCOSITY OR BRONCHIAL SECRETIONS IS THE FROM ON THERAPEUTIC EFFECT CF WATER ELASTICITY OTHER SPUTUM PROPERTIES OF
7 ; THOSE AS DEGRADED SUBJECTS ARE FROM GLYCOPROTEINS COMPARED TO NORMAL MUCUS CF IN DIFFERENTLY PATIENTS
8 ; AND DESCRIBED HISTOCHEMICAL DIFFERENCES BETWEEN NORMAL CF EPITHELIA HAVE BEEN RESPIRATORY WHAT
9 ; AND LIVER METABOLISM DISEASE IS THE ASSOCIATION BETWEEN CF CIRRHOSIS VITAMIN IN WHAT
10 ; WHAT PATIENTS THERAPY IS THE WITH ROLE CF VITAMIN IN OF
11 ; AND ILEUS IS THE MECONIUM DIFFERENCE BETWEEN PLUG SYNDROME WHAT
12 ; WHAT BOWEL DESCRIBED PATIENTS SMALL ABNORMALITIES THE ACID TRANSPORT CF HAVE AMINO BEEN IN OF
13 ; OF BIOCHEMICAL ARE OR THE PANCREATITIS CLINICAL FEATURES CF IN PATIENTS WHAT
14 ; OF BE TESTS PERFORMED EXOCRINE EVALUATION CAN WITH THE PANCREATIC NON-INVASIVE CF FOR FUNCTION IN PATIENTS WHAT
15 ; OF HEPATIC ARE OR MANIFESTATIONS THE COMPLICATIONS CF WHAT
16 ; WHAT NEONATAL PERIOD AND ILEUS EXCLUDE LIVER ARE DISEASE THE MECONIUM AFTER COMPLICATIONS GASTROINTESTINAL CF OF
17 ; OF MOST ENZYME SUPPLEMENTS TREATMENT PATIENTS IS THE EFFECTIVE PANCREATIC CF FOR REGIMEN USE IN WHAT
18 ; DIETARY BILE BENEFIT WITH IS THERAPEUTIC TO SALTS SUPPLEMENTATION CF PATIENTS OF
19 ; ENZYME WHAT PATIENTS THERAPY REPORTED PANCREATIC COMPLICATIONS CF HAVE BEEN IN OF
20 ; WHAT SUPPLEMENTS TREATMENT FATTY ESSENTIAL WITH IS THE ACID EFFECT CF PATIENTS OF
21 ; DOES INSUFFICIENCY AFFECT OR ABILITY IRON PANCREATIC TO CF METABOLIZE ABSORB IN PATIENTS THEIR
22 ; WHAT IS THE NON-CAUCASIAN CF POPULATIONS FREQUENCY IN OF
23 ; CONGENITAL OR CONDITIONS WITH HEREDITARY FOUND ASSOCIATION CF DISEASES HAVE BEEN IN WHAT
24 ; WHAT INCOMPLETELY MANIFESTED ARE CHARACTERISTICS WHOM IS THE CF IN PATIENTS OF
25 ; GENETIC BASIS INVOLVES GENE IS THE EVIDENCE CF FOR MORE THAT THERE THAN ONE WHAT
26 ; ADVANTAGE HETEROZYGOTE IS THE CF IN WHAT
27 ; CONCORDANCE WHAT PAIRS BIOCHEMICAL OR MANIFESTATIONS SIBLING IS THE WHOM BOTH CLINICAL CF HAVE IN OF
28 ; OF WHAT MALE FERTILITY IS THE CF IN INCIDENCE
29 ; WHAT REPRODUCTIVE MALE OR IS THE FEMALE CF SYSTEM IN PATHOLOGY OF
30 ; GENETIC RESULTS WHAT FAMILIES ARE COUNSELING WITH THE CF CHILDREN OF
31 ; OF AND FAMILIES MAJOR ARE OR EFFECTS THE ON SOCIAL CF PSYCHOLOGICAL THEIR PATIENTS WHAT
32 ; PATIENTS WITH THERAPY COMPLIANCE PRESCRIBED CF FACTORS INFLUENCE IN WHAT
33 ; TESTS OR CONDITIONS TO FACTORS ERRONEOUS SWEAT LEAD WHAT
34 ; QUANTITATIVE THAN ANALYSIS THEIR AVAILABLE ARE CHLORIDE GIBSON-COOKE SWEAT WHAT TESTING THE ALTERNATIVE FOR TITRIMETRIC OTHER TEST AND PILOCARPINE CLASSICAL WITH IONTOPHORESIS ADVANTAGES RELATIVE TECHNIQUES DISADVANTAGES OF
35 ; TESTS ANY TO FOUND CF NORMAL HAS HAVE PATIENT BEEN CONSISTENTLY SWEAT
36 ; WHAT PATIENTS FROM IS THE CONCENTRATION CF POTASSIUM IN SWEAT OF
37 ; OF AND SCREENING NEWBORN CONTRIBUTE RESULTS AVAILABLE TESTS ARE INFANTS TO THESE CF FOR FACTORS ERRONEOUS TECHNIQUES WHAT
38 ; CAN BE PRENATALLY DIAGNOSED CF
39 ; BE MAY HOW CF FOR IDENTIFIED HETEROZYGOTES
40 ; OF BE NEONATAL PERIOD DIAGNOSIS MAY THE USEFUL CF THAN FOR OTHER TEST SWEAT TECHNIQUES BEYOND WHAT
41 ; METABOLISM IS NORMAL CF IN VITAMIN PATIENTS
42 ; WHAT METABOLISM OCCUR OR SECRETION ABNORMALITIES INSULIN CF IN PATIENTS OF
43 ; SALT SODIUM AND/OR IS TRANSPORT/PERMEABILITY CHLORIDE CF ABNORMAL IN
44 ; ENZYMATIC AND ARE OR FIBROBLASTS FROM NON-CF DIFFERENCES BETWEEN CF STRUCTURAL THERE PATIENTS WHAT
45 ; WHAT PATIENTS DESCRIBED METABOLISM ABNORMALITIES CF PROSTAGLANDIN HAVE BEEN IN OF
46 ; OF AND PATIENTS GALACTOSYLTRANSFERASE ARE FROM THE ENZYMES ACTIVITY CF PROPERTIES WHAT
47 ; IN AND DESCRIBED SUBJECTS OF HORMONES METABOLISM OR THE NORMAL BETWEEN DIFFERENCES CF FUNCTION HAVE BEEN PATIENTS WHAT
48 ; AT FROM FIBROBLASTS RATE GROW NORMAL CF DO PATIENTS
49 ; METABOLISM OR IS METHYLATION NORMAL CF RNA IN POLYAMINE PATIENTS
50 ; OF PATIENTS DESCRIBED METABOLISM OR THE SYNTHESIS CYCLIC NUCLEOTIDES CF DEFECTS HAVE IN BEEN WHAT
51 ; DESCRIBED PATHOGENETIC OR SOME PATIENTS PLAY FIBROSIS ARE THOUGHT FACTORS '' HAVE BEEN IN WHAT `` SECRETED ROLE MOLECULES BIOLOGICALLY CYSTIC CIRCULATING ACTIVE TO CF UNIDENTIFIED
52 ; WHAT ABOUT KNOWN IS CF IN PATIENTS PROLACTIN
53 ; COLONIZATION DOES PROTECT OR IGA CF AGAINST INFECTION BACTERIAL SECRETORY PATIENTS
54 ; WHAT HYPERSENSITIVITY RELATIONSHIP LUNG DISEASE OR IS THE ALLERGY TO CF IN PATIENTS OF
55 ; WHAT AND ENDOGENOUS ANTIPROTEASES OF ARE OR ORIGIN PROTEASES THE LUNGS BETWEEN CF BACTERIAL IN PATIENTS INTERACTIONS
56 ; PATIENTS AND RELATIONSHIP PULMONARY NUTRITION IS THE DEFENSES BETWEEN AGAINST INFECTION CF BACTERIAL HOST IN WHAT
57 ; WHAT PSEUDOMONAS AERUGINOSA CIRCULATING IS THE ANTIBODIES TO ROLE CF PATHOPHYSIOLOGIC IN PATIENTS OF
58 ; PULMONARY IS THE RESPONSE TO CF INFECTION IMMUNOLOGIC IN PATIENTS WHAT
59 ; PATIENTS ABNORMALITIES FOUND CF IMMUNOLOGIC HAVE BEEN IN WHAT
60 ; WHAT CIRCULATION ARE EFFECTS PULMONARY THE ON CF OF
61 ; DEFECT PATIENTS TRACT CLEARANCE IS THE TRANSPORT CF MUCOCILIARY THERE IN RESPIRATORY OF
62 ; WHAT LUNG ARE DISEASE THE CLINICAL FEATURES CF IN PATIENTS OF
63 ; OF AIRWAY INFLAMMATION BIOCHEMICAL ARE OR CHARACTERISTICS THE MICROSCOPIC CF IN PATIENTS WHAT
64 ; PERIODS LUNG DOES GREATER HOW WITH CHANGE TIME CF THAN FUNCTION DAY IN PATIENTS
65 ; WHAT ARE PULMONARY ABNORMALITIES THE CF FUNCTION IN PATIENTS OF
66 ; WHAT LUNG ARE DISEASE THE FEATURES CF PATHOLOGIC IN PATIENTS OF
67 ; OF RESPIRATORY AN FAILURE IS PROGNOSIS THE EPISODE WHO FOR HAVE HAD PATIENTS WHAT
68 ; WHAT BRONCHODILATORS ARE EFFECTS THE CF IN PATIENTS OF
69 ; BEST PNEUMOTHORAX WAY IS THE TO CF TREAT IN PATIENTS WHAT
70 ; OF AND TREATMENT IS THE PROGNOSIS CF FOR HEMOPTYSIS IN PATIENTS WHAT
71 ; AND CYSTIC FIBROSIS WITH IS PROGNOSIS INFANTS THE WHEEZING FOR WHAT
72 ; BEST NASAL TREATMENT IS THE POLYPS CF FOR IN PATIENTS WHAT
73 ; BRONCHIAL HOW IS EFFECTIVE LAVAGE CF IN PATIENTS
74 ; WHAT RESULTS RESPIRATORY ARE VENTILATION MECHANICAL WITH FAILURE THE CF IN PATIENTS OF
75 ; PATIENTS BEST TREATMENT PULMONARY AND/OR IS THE HYPERTENSION CF FOR PULMONALE COR IN WHAT
76 ; WHAT LUNG ARE EFFECTS EXERCISE TRAINING THE PROGRAMS ON CF FUNCTION IN PATIENTS OF
77 ; OF PROMOTING ARE FROM CLEARANCE THE EFFECTIVE LUNGS MUCUS CF TECHNIQUES IN PATIENTS WHAT
78 ; SPECIAL OR PHARMACODYNAMICS PATIENTS DIFFERENT TREATMENT PECULIAR ARE IE THERE IN WHAT ANTIBIOTICS CONSIDERATIONS THE PROBLEMS FOR OTHER WITH TO CF OF
79 ; WHAT ANTIBIOTICS TREATMENT IS THE ROLE CF ORALLY ADMINISTERED IN PATIENTS OF
80 ; AND AMINOGLYCOSIDES COMBINATION THERAPY IS THE WITH EFFECTIVE EVIDENCE MORE THAN THAT EITHER PENICILLINS ALONE SEMISYNTHETIC WHAT
81 ; TREATMENT AGENTS ARE HOW THE EFFECTIVE MUCOLYTIC CF INHALATIONS IN PATIENTS OF
82 ; WHAT TREATMENT LUNG DISEASE IS THE ROLE CF AEROSOLS IN PATIENTS OF
83 ; WHAT BY MACROPHAGES LEUKOCYTES ALVEOLAR LUNG DISEASE OR IS THE POLYMORPHONUCLEAR ROLE CF BACTERIAL PHAGOCYTOSIS IN PATIENTS OF
84 ; AND INFLUENZAE PSEUDOMONAS AERUGINOSA RELATIONSHIP IS THE BETWEEN CF HAEMOPHILUS IN PATIENTS WHAT
85 ; LUNG ORGANS SO THE IF CF DEVELOP INFECTION DO OTHER EVER THAN IN PATIENTS WHAT
86 ; WHAT PSEUDOMONAS INFLUENZAE PATIENTS AERUGINOSA BACTERIA LUNG STAPHYLOCOCCUS OR DISEASE IS THE ROLE CF THAN HAEMOPHILUS OTHER PATHOGENESIS IN AUREUS OF
87 ; WHAT FUNGI LUNG DISEASE IS THE ROLE CF PATHOGENESIS IN PATIENTS OF
88 ; WHAT LUNG DISEASE IS THE ROLE CF VIRAL INFECTION IN PATIENTS OF
89 ; WHAT PSEUDOMONAS AERUGINOSA EPIDEMIOLOGY OR IS THE SPREAD TO CF DO SPECIFICALLY OTHER INDIVIDUALS FAMILY IN PATIENTS OF
90 ; OF PSEUDOMONAS AERUGINOSA ARE STRAINS THE RESPONSIBLE APPEARANCE CF FOR MUCOID FACTORS IN PATIENTS WHAT
91 ; WHAT EXOCRINE LUNG INSUFFICIENCY ARE MANIFESTATIONS DISEASE OR THE PANCREATIC CF THAN UNUSUAL OTHER OF
92 ; OF WITH IS PROGNOSIS THE SURVIVAL CF FOR PATIENTS WHAT
94 ; AVAILABLE MODELS ARE TO RELEVANT CF WHICH ANIMAL WHAT
95 ; WHAT PATIENTS MUSCLE OR ABNORMALITIES STRUCTURE FOUND CF FUNCTION SKELETAL HAVE BEEN IN OF
96 ; OF INCREASED DISEASE AN OR IS EG CARIES DENTAL PERIODONTAL PROBLEMS CF THERE IN PATIENTS INCIDENCE
97 ; BY OXYGEN CELLS BLOOD IS TRANSPORT RED CF ABNORMAL IN PATIENTS
98 ; WHAT AND NERVOUS CENTRAL ARE EFFECTS AND/OR THE DEVELOPMENT ON BRAIN CF FUNCTION SYSTEM OF
99 ; OF ARE ABNORMALITIES CF THERE IN PATIENTS TASTE
100 ; OF AND WHAT PATIENTS TREATMENT IS THE OSTEOARTHROPATHY CF FOR IN HYPERTROPHIC INCIDENCE